Kornimate/medical-research-clean huggingface dataset:
ovarian reserve in patients with psoriasis

Conditions: Psoriasis; Anti Mullerian Hormone; Ovarian Reserve

Summary: psoriasis is a common autoimmune disease. it affects women of all ages including reproductive years. autoimmune diseases including psoriasis are linked to premature ovarian reserve. this study aims to measure serum hormones including fsh,lh,e2,prl and amh (indicators of ovarian reserve) in women with and without psoriasis.

psoriasis is a common autoimmune disease. it affects women of all ages including reproductive years. almost 75% of patients are diagnosed before the age of 40. there is also increased evidence on autoimmune disease and their link to premature ovarian failure.ovarian reserve is important for the reproductive period. the measurements of serum hormones including follicle stimulating hormone (fsh),luteinizing hormone (lh),prolactin (prl), estradiol (e2) and anti-mullerian hormone (amh) will give us an idea about the ovarian reserve. the investigators aim is to measure ovarian reserve parameters in patients newly diagnosed with psoriasis and to compare them to healthy controls. serum fsh,lh,e2,prl and amh will be measured on the 3rd day of the cycle.the serum hormone levels will be compared between women with psoriasis and women without psoriasis

Eligibility criteria:
inclusion criteria: * reproductive age group women: 18-40 years * women diagnosed with psoriasis (case group) * women without psoriasis (control group) exclusion criteria: * women with pcos (polycystic ovary syndrome) * history of ovarian surgery * body mass index (bmi) over 30 * women with other autoimmune diseases including hashitomo thyroiditis * women with family history of premature ovarian insufficiency (poi) * women with infertility * psoriasis using systemic drugs including steroids and immunosuppressive therapy.

Keywords: psoriasis anti mullerian hormone ovarian reserve antral follicle count
comparison of 7-day ppi-based standard triple therapy and 10-day bismuth quadruple therapy for h. pylori eradication

Conditions: Helicobacter Pylori Infection; Family History of Stomach Cancer

Summary: in this randomized controlled trial, we investigate the effect of 10-day bismuth quadruple therapy in comparison with that of 7-day ppi-based standard triple as 1st line treatment for h. pylori.

current helicobacter pylori management guidelines recommend proton-pump inhibitor (ppi)-clarithromycin containing triple therapy as 1st line treatment. however, in korea, eradication rates of ppi-clarithromycin containing triple therapy have been decreased to less than 80% due to increased clarithromycin resistance. in areas of high clarithromycin resistance (resistance rate more than 15%), guidelines recommend bismuth quadruple therapy as a 1st line treatment for h. pylori eradication. clarithromycin resistance rates reported from 15.7% to 42.1% in korea, thus, bismuth quadruple therapy may be better 1st line treatment than ppi-clarithromycin containing triple therapy. however, only one limited study was performed to compare effects of the both treatment regimens in korea. thus, studies evaluating the effect of 10-day bismuth quadruple therapy as the first line treatment for h. pylori infection.

Eligibility criteria:
inclusion criteria: * men and women aged 18 or more including following conditions * family history of gastric cancer * post endoscopic resection status for early gastric cancer or adenoma * peptic ulcer disease (benign gastric ulcer and duodenal ulcer) * chronic gastritis * non-ulcer dyspepsia * healthy adults who want to receive h. pylori treatment * h. pylori positive by urea breath test, histology, or rapid urease test exclusion criteria: * history of h. pylori eradication therapy * history of stomach operation * other organ cancer within 5 years * liver cirrhosis or hepatic insufficiency * renal insufficiency * current treatment for serious medical condition which may hinder participation * contraindication or allergy history for h. pylori treatment regimens * mental incompetence to understand and sign informed consent * incompatible conditions to be included into the trial by investigators' decision * inability to provide an informed consent * history of treatment for peptic ulcer disease

Keywords: ppi standard triple therapy bismuth quadruple therapy helicobacter
immunoadsorption of lps, c5a and il-6 in severe sepsis and septic shock (isass-1)

Conditions: Septicemia

Summary: the purpose of this study is to determine whether immunoadsorption of lps, il-6 and c5a reduces systemic hyperinflammation, improves immune function and improves organ function in patients with severe sepsis and septic shock


Eligibility criteria:
inclusion criteria: * diagnosis of severe sepsis or septic shock (accp/sccm) * presence of 4 sirs criteria/indicators * suspected or proven infection (refer also to: 1.) * age 18-80 * apache ii score \> 18 * at least one acute organ dysfunction (renal/pulmonary/hemodynamics/cerebral) exclusion criteria: * suspected or proven pregnancy * absolute contraindication for anticoagulation (active bleeding) * absolute iga-deficiency * history of anaphylactic reaction to egg-albumin * participants in other clinical trials (\<12 wks. prior to study inclusion)
traditional chinese medicine for severe covid-19

Conditions: COVID-19

Summary: in december 2019, a new type of pneumonia, covid-2019 outbroke in wuhan ,china, and currently the infected has been reported in more than at least 75 countries. patients with severe covid-19 have rapid disease progression and high mortality rate. this may attribute to the excessive immune response caused by cytokine storm. strategies based on anti-virus drugs and treatments against symptoms have now been employed. however, these managements can't effectively treat the lethal lung injury and uncontrolled immune responses, especially in the elderly with severe covid-19. traditional chinese medicine (tcm), which treats the disease from anther perspective, has achieved satisfactory results. national health commission of china released a series of policies to enhance the administration of tcm prescriptions. this study is aimed to evaluate the efficacy and safety of traditional chinese medicine as an adjuvant treatment for severe covid-19.


Eligibility criteria:
key inclusion criteria: 1. patients were diagnosed as severe covid-19 according to the coronavirus disease (covid-19) treatment guidance (six edition) 2. patients received a combined treatment of tcm and conventional therapy, or only conventional therapy. key exclusion criteria: 1. age \>85 years 2. after cardiopulmonary resuscitation 3. patients combined with other organ failure or conditions need icu monitoring and treatment, such as severe liver disease, severe renal dysfunction, upper gastrointestinal hemorrhage, disseminated intravascular coagulation. 4. respiratory failure and need mechanical ventilation

Keywords: covid-19 traditional chinese medicine pneumonia coronavirus
oxygen reserve index and prevention of hyperoxemia

Conditions: Hyperoxemia; Oxygen Reserve Index; Hyperoxia; Fraction of Inspired Oxygen

Summary: in patients under general anesthesia, the oxygen level (fio2) used in inspiration is usually adjusted by monitoring the peripheral oxygen saturation level (spo2). as a non-invasive method, spo2 monitoring is known as one of the required methods that can be used to adjust fio2 and detect and treat hypoxemia. while spo2 approaching 100% matches the value of 128 mmhg in arterial partial oxygen pressure (pao2), in cases where pao2 increases more, the investigators cannot follow this situation with spo2 and cannot prevent hyperoxemia. as stated in the literature, hyperoxemia has positive effects in general anesthesia and intensive care, as well as negative effects such as increased inflammation, oxidative stress and ischemia-reperfusion. in addition, acute lung injury, development of atelectasis, increased mortality, and critical illness rates have been associated with hyperoxemia in many publications. the only way the investigators can use to measure the level of hyperoxemia seems to be arterial blood gas analysis, and this method limits the investigators use because it is invasive. the oxygen reserve index (ori™) (masimo corp., irvine, ca, usa) is a variable related to real-time oxygenation reserve status in the mildly hyperoxemic range (approximately 100 - 200 mmhg pao2). ori can be defined as a multi-wavelength, noninvasive pulse co-oximetry sensor. ori is a dimensionless index ranging from 0.00 (no reserve) to 1.00 (maximum reserve) depending on the oxygenation reserve status. there are very few studies in the literature using ori to detect hyperoxemia. the investigators thought that if fio2 levels used in preoxygenation, anesthesia maintenance and recovery stages in day surgeries were correlated with ori levels, a threshold value could be determined for fio2 levels during anesthesia stages in cases where invasive arterial blood gas could not be followed. this study aims to determine the relationship between spo2, fio2 and ori during general anesthesia, to investigate the usefulness of ori in determining the fio2 threshold value during anesthesia stages as an indicator of hyperoxemia, and to investigate the effects of these values on the hemodynamics, recovery, agitation and nausea-vomiting states of the patients.


Eligibility criteria:
inclusion criteria: * patients with an american society of anesthesiologists (asa) score of 1 exclusion criteria: * patients with an american society of anesthesiologists (asa) score of 2 and above

Keywords: oxygen reserve index hyperoxemia hyperoxia fraction of inspired oxygen
auto-inoculation of a wart in multiple viral warts

Conditions: Viral Wart; Delayed Hypersensitivity

Summary: this study is being conducted to see effectiveness of auto-inoculation of a wart in multiple viral warts. patients with recurrent, multiple warts of all types, are being recruited for the study. a wart is excised, minced and then inoculated in a subcutaneous pocket made on the volar aspect of forearm. patients are to be reviewed after every 4 weeks to note any reduction in number warts.

a single arm, phase 1, clinical study

Eligibility criteria:
inclusion criteria: * individuals having 5 or warts * individuals having any types of warts exclusion criteria: * individuals using any other treatment for warts

Keywords: autoinoculation viral warts hypersensitivity immunology
zilebesiran as add-on therapy in patients with hypertension not adequately controlled by a standard of care antihypertensive medication (kardia-2)

Conditions: Hypertension

Summary: the purpose of this study is to evaluate the effect of zilebesiran on systolic and diastolic blood pressure and to characterize the pharmacodynamic (pd) effects and safety of zilebesiran as add-on therapy.


Eligibility criteria:
inclusion criteria: * office sbp at screening as follows: 1. ≥155 mmhg and ≤180 mmhg for patients with untreated hypertension 2. ≥145 mmhg and ≤180 mmhg for patients on antihypertensive medications * 24-hour mean sbp ≥130 mmhg and ≤160 mmhg by abpm after at least 4 weeks of run-in exclusion criteria: * secondary hypertension, orthostatic hypotension * elevated potassium \>5 milliequivalents per liter (meq/l) * estimated glomerular filtration rate (egfr) of \<30 ml/min/1.73m\^2 * received an investigational agent within the last 30 days * type 1 diabetes mellitus, poorly controlled type 2 diabetes mellitus, or laboratory evidence of diabetes during screening without known diagnosis of diabetes * history of any cardiovascular event within 6 months prior to randomization * history of intolerance to sc injection(s)

Keywords: high blood pressure hypertension hypertensive sirna angiotensinogen agt
early indicators of chronic rejection in lung transplant

Conditions: Chronic Rejection in Lung Transplant; Cytokine Production in Bos Post Lung Transplant

Summary: the purpose of this research is to discover the different patterns of cytokine production in patients who may develop bronchiolitis obliterans syndrome-0p (bos-0p) which means ongoing rejection. this is an early indicator of chronic rejection in lung transplant recipients. these cytokines can be detected in the bronchoalveolar (lung) and tissue samples of lung transplant recipients.

lung transplant recipients are routinely followed in clinic every three months after the first year post-transplant. spirometry with measurement of fev1, fvc and fef25-75 are obtained at each visit. in addition, lung transplant recipients undergo surveillance bronchoscopy at one, three, six, nine and twelve months. all bronchoscopy specimens that are obtained for this study will be obtained during bronchoscopies that were scheduled per the physician caring for the patient. an extra 90 cc of sterile solution will be instilled into bronchus and two extra transbronchial biopsies will be performed in addition to the routine bronchoscopic procedure. routinely, 4-8 transbronchial biopsy samples are obtained from the transplanted lung. two specimens will be randomly selected for study and the rest will undergo routine histopathologic study. the study biopsies will be set aside and processed. the study visits for this research will occur at the same time as standard of care post transplant visits. we will collect subject's history,demographic of subject's transplant data,donor procurement information, physical exam information, pregnancy tests,blood test and spirometry results from the visits mentioned above.

Eligibility criteria:
inclusion criteria: * lung transplant recipients between the ages of 18 and 65 years old * all patients must be able to give written informed consent exclusion criteria: * lung transplant recipients who are unable to undergo bronchoscopy * lung transplant recipients who are unable to give informed consent

Keywords: chronic rejection, lung transplant, cytokines, bos
study of hqk-1004 and valganciclovir to treat epstein-barr virus (ebv) - positive lymphoid malignancies or lymphoproliferative disorders

Conditions: Lymphoid Malignancies; Lymphoproliferative Disorders

Summary: the purpose of this study is to determine if treatment with hqk-1004 and valganciclovir will result in complete or partial responses in patients with ebv-positive lymphoid malignancies or lymphoproliferative disorders.


Eligibility criteria:
inclusion criteria: * histologically confirmed lymphoid malignancy or lymphoproliferative disorder with ebv detected by either immunohistochemistry or in situ hybridization. pathology can be assessed on either a current or previous biopsy. all disease stages are eligible * disease that is refractory or relapsed after at least one prior standard therapeutic regimen, which includes biologic agents (e.g., monoclonal antibodies), chemotherapy or chemoradiotherapy regimens. prior therapy may include high dose chemotherapy and stem cell rescue or bone marrow transplantation * bidimensionally measurable disease by computerized tomography (ct) or magnetic resonance imaging (mri; patients with sensitivity to contrast or for tumor types that are less accurately measured by ct) scan or physical measurement (cutaneous lesions only) with at least 1 lesion ≥ 10 mm in the greatest diameter. pet-ct should be used at baseline for patients with hodgkin's disease (hd) or diffuse large b-cell lymphoma (dlbcl). * absolute neutrophil count ≥ 500/mm3 and platelet count ≥ 50,000/mm3 * bilirubin ≤ 2.0 times upper limit of normal (uln) with the exception of patients with gilbert's syndrome (bilirubin ≤ 3.5 times uln allowed), and both ast and alt ≤ 3 times uln * serum creatinine ≤ 2.0 mg/dl exclusion criteria: * patients who have not recovered from previous treatment with chemotherapy * patients who have been treated with biologic agents within two weeks prior to first dose of hqk-1004 * uncontrolled ischemic heart disease or uncontrolled congestive heart failure, or myocardial infarction within the past 3 months
treatment of gingival recession with tunnel technique using connective tissue graft and injectable platelet rich fibrin

Conditions: Gingival Recession

Summary: gingival recession is a common periodontal problem. consequences include teeth sensitivity, poor esthetics and impaired oral hygiene access. mild cases are managed by optimizing oral hygiene measures, correction of any causative factor such as faulty tooth brushing, improper dental restoration or denture clasp. prescription of desensitization products such as specific tooth gels or mouth washes can manage the sensitivity problem. deeper recession defects need to be addressed by surgical procedures. coronally advanced flap with connective tissue graft is the gold standard procedure. however, it has some drawbacks due to the need for papillary incisions and vertical incisions in some cases. within the era of minimally invasive periodontology, tunnel technique with connective tissue graft showed results comparable to coronally advanced flap with connective tissue graft but with some limitations. addition of another agent may enhance the results of tunnel technique. injectable platelet rich fibrin is known for its content of growth factors and effects on soft tissue healing. aim: the study aim is to compare the surgical management of gingival recession with tunnel technique using connective tissue graft and injectable platelet rich fibrin to tunnel with connective graft without injectable platelet rich fibrin. methodology: 30 patients with miller class i or ii gingival recession will be enrolled. 15 in the test group (tunnel+ ctg+ i-prf) and 15 in control group (tunnel+ ctg). clinical evaluation at 6 months

30 patients with miller class i/ii gingival recession will be enrolled in this study. 15 patients will be treated using tunnel technique and palatal connective tissue graft inserted and sutured under the prepared tunnel after being soaked in injectable platelet rich fibrin for 15 minutes. the tunnel with the underlying graft will be advanced coronally. (test group) the other 15 patients will be treated the same way as in the first group but without soaking the graft in injectable platelet rich fibrin. (control group) clinical parameters will be evaluated at baseline and 6 months follow-up except post-operative pain which will be assessed after 10 days. histologic examination of small piece of the graft will be done to assess if there is true saturation of growth factors inside the graft.

Eligibility criteria:
inclusion criteria: * more than 21 years old * systemically healthy * presence of miller class i/ii gingival recession * presence of identifiable cej exclusion criteria: * smoking * systemic disease that contraindicates surgical procedures. * poor compliance with oral hygiene measures * necrotizing gingival conditions * ongoing active periodontitis

Keywords: tunneling gingival recession injectable platelet rich fibrin minimally invasive periodontology
acostream use in patients with high risk and intermediate-risk acute pulmonary embolism

Conditions: Pulmonary Embolism (PE)

Summary: the registry is to evaluate the safety and feasibility of catheter-directed aspiration for patients with high-risk and intermediate-high-risk pulmonary embolism using acostream.

the registry is a prospective, multicenter, observational study involving 130 patients across up to seven sites in china. the aim of this study is to evaluate the safety and feasibility of catheter-directed thrombectomy using acostream in patients with high-risk and intermediate-high-risk pulmonary embolism. the primary endpoint of the study is the efficacy and safety of pulmonary thrombus removal, assessed by reduction of ventricular strain, decrease in vascular obstruction, overall clinical improvement, and the early mortality rate from pulmonary embolism. secondary endpoints include the total mortality rate of pe and the incidence of complications in the procedure.

Eligibility criteria:
inclusion criteria: * 18≤age≤85 * clinical symptoms and presentation consistent with pulmonary embolism (pe). * pe symptoms duration ≤ 14 days. * high risk pe patients with absolute contraindications to systemic thrombolysis or its failure (refractory circulatory collapse) not eligible for surgical embolectomy. * intermediate-high risk pe patients with right ventricle dysfunction (right ventricle/ left ventricle \>0.9) confirmed by computed tomography pulmonary angiography or transthoracic echocardiography. exclusion criteria: * pregnancy. * refusal to sign the informed consent form. * presence of intracardiac thrombus. * presence of chronic left heart failure with an ejection fraction lower than 30% diagnosed thrombophilia. * history of severe or chronic pulmonary hypertension. * serum creatinine level higher than 1.8 mg/dl. * known serious and uncontrolled sensitivity to radiographic agents.
study to evaluate the efficacy of enbrel as a biological treatment in moderate to severe plaque psoriasis patients

Conditions: Plaque Psoriasis

Summary: this study is to evaluate available local data in iraqi patients with moderate to severe psoriasis on enbrel treatment with regards to efficacy, treatment regimen adherence and patient characterization (i.e. age, gender, smoking status) using data from the dermatologists in baghdad teaching hospital registry


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of moderate to severe plaque psoriasis receiving etanercept treatment for a minimum duration of 1 year. * age ≥18 years old. * no history of using a biological treatment, other than etanercept, for treatment of moderate to severe plaque psoriasis or any other reason. exclusion criteria: * etanercept use for treatment moderate to severe plaque psoriasis less than 1 year duration. * previous use of other biological treatments for any reason
prospective cohort assessing the role of the genotoxin colibactin from escherichia coli b2 in the genesis of nash

Conditions: Non-alcoholic Fatty Liver Disease

Summary: in a population of patients with non alcoholic fatty liver disease (nafld), the investigators will compare the composition of the gut microbiota from patients with simple steatosis with that with steatohepatitis. the purpose of this study is to determine if the pathogenic escherichia coli to the b2 group and producing the genotoxin colibactin is a factor for developing nash.

gut microbiota composition is now linked to the onset of obesity, metabolic disorders, and non alcoholic fatty liver disease . while simple steatosis has benign prognosis, steatohepatitis (nash) leads to cirrhosis and hepatocarcinoma and increases cardiovascular and cancer- related mortality. some escherichia coli (e. coli) belonging to the b2 phylogenetic group are involved in many diseases. those producing the genotoxin colibactin are in addition known to induce a chronic alteration of intestinal permeability, one of the major factors leading to nash.

Eligibility criteria:
inclusion criteria: * nafld * indication of liver biopsy exclusion criteria: * presence of any other cause of liver or steatosis * alcohol consumption exceeding 30 g / day for a men and 20 g / day for a woman * a history of decompensated cirrhosis * treatment with prebiotics, probiotics or antibiotics in the month prior to inclusion * chronic gastrointestinal disease or history of gastrointestinal surgery * pregnancy or breastfeeding * patient under guardianship

Keywords: gut microbiota non alcoholic steato hepatitis steatohepatitis escherichia coli colibactin